NEW YORK — CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients. By Rebecca Robbins ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...